相关实验视频

Updated: Apr 27, 2026

Escherichia coli-Based Cell-Free Protein Synthesis: Protocols for a robust, flexible, and accessible platform technology

Escherichia coli-Based Cell-Free Protein Synthesis: Protocols for a robust, flexible, and accessible platform technology

Published on: February 25, 2019

设计一个强大的大肠杆菌W平台,用于可扩展的生产黄-O-葡萄糖酸

Darwin Carranza-Saavedra^1,2, Jesús Torres-Bacete¹, Elodie Bouju³

¹Systems Biotechnology Group, Department of Systems Biology, Centro Nacional de Biotecnología, CSIC, Madrid, Spain.

Microbial biotechnology

|October 9, 2025

概括

埃舍里希亚大肠杆菌 (Escherichia coli W) 通过使用糖糖有效地糖化黄,克服了溶解性和生物可用性问题. 这种优化的微生物宿主可以实现可扩展的生物生产有价值的黄类葡萄糖体,如素-7-O-葡萄糖体.

科学领域:

生物技术是生物技术.
代谢工程是代谢工程.
合成生物学合成生物学

背景情况:

黄类化合物具有重要的制药,化品和食品价值.
溶解度和生物利用度差,阻碍了黄类的应用.
目前的生物技术糖化方法面临的挑战是尿素二酸葡萄糖 (UDPG) 的成本和黄类毒性.

研究的目的:

为了确定大肠杆菌Escherichia coli W作为一种最佳的微生物宿主,用于类糖化.
通过优化糖糖代谢和UDPG生产来提高糖化效率.
开发一种可扩展的生物工艺,用于生产黄类葡萄糖体,特别是素-7-O-葡萄糖体 (C7O).

主要方法:

利用大肠杆菌Escherichia coli W作为微生物宿主,利用糖作为碳和UDPG来源.
采用适应性实验室进化 (ALE) 和代谢工程来优化糖糖代谢和葡萄糖转向UDPG.
在3L生物反应堆中通过实验室规模和料批量生物工艺验证了平台,用于C7O生产.

主要成果:

与大肠杆菌E. coli K12相比,大肠杆菌W表现出优越的黄类耐受性和糖化能力.
优化的大肠杆菌W实现了高度C7O的产生,在食批量过程中达到1844 mg/L (3.3 mM).
提取后82.1% (1515 mg/L C7O) 的产量证实了该过程的效率和可扩展性.

结论:

大肠杆菌 (Escherichia coli W) 是一种高度有效的宿主,用于微生物对黄酸盐 (flavonoids) 的糖化.
开发的生物工艺克服了黄胺溶解度和生物可用性的关键限制.
该平台为工业生物生产的黄类葡萄糖酸提供了一个高效和可扩展的途径.

关键词:

在UDP-葡萄糖生产过程中.适应性实验室进化的演变.生物过程优化优化黄类糖基化法黄类糖基化法代谢工程是代谢工程.糖糖的代谢糖糖的代谢

更多相关视频

Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade

Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade

Published on: August 14, 2019

A Customizable Approach for the Enzymatic Production and Purification of Diterpenoid Natural Products

A Customizable Approach for the Enzymatic Production and Purification of Diterpenoid Natural Products

Published on: October 4, 2019

相关概念视频

Bioreactor Controls-III

Bioreactor Controls-III

Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...

Production of Pharmaceuticals

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...